Palatin Technologies, Inc. (PTN)
12.70
-0.38
(-2.91%)
USD |
NASDAQ |
Sep 04, 16:00
12.79
+0.09
(+0.71%)
After-Hours: 20:00
Palatin Technologies Research and Development Expense (Quarterly) : 3.517M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 3.517M |
| December 31, 2025 | 4.320M |
| September 30, 2025 | 2.526M |
| June 30, 2025 | 1.970M |
| March 31, 2025 | 3.755M |
| December 31, 2024 | 3.430M |
| September 30, 2024 | 5.744M |
| June 30, 2024 | 4.672M |
| March 31, 2024 | 7.160M |
| December 31, 2023 | 5.554M |
| September 30, 2023 | 5.015M |
| June 30, 2023 | 7.406M |
| March 31, 2023 | 4.830M |
| December 31, 2022 | 4.368M |
| September 30, 2022 | 6.027M |
| June 30, 2022 | 7.436M |
| March 31, 2022 | 4.980M |
| December 31, 2021 | 5.426M |
| September 30, 2021 | 3.485M |
| June 30, 2021 | 3.482M |
| March 31, 2021 | 2.510M |
| December 31, 2020 | 4.011M |
| September 30, 2020 | 2.924M |
| June 30, 2020 | 3.933M |
| March 31, 2020 | 3.641M |
| Date | Value |
|---|---|
| December 31, 2019 | 3.258M |
| September 30, 2019 | 3.128M |
| June 30, 2019 | 4.329M |
| March 31, 2019 | 3.944M |
| December 31, 2018 | 2.962M |
| September 30, 2018 | 3.623M |
| June 30, 2018 | 5.288M |
| March 31, 2018 | 7.069M |
| December 31, 2017 | 6.046M |
| September 30, 2017 | 14.16M |
| June 30, 2017 | 17.26M |
| March 31, 2017 | 9.062M |
| December 31, 2016 | 8.135M |
| September 30, 2016 | 11.23M |
| June 30, 2016 | 10.52M |
| March 31, 2016 | 10.68M |
| December 31, 2015 | 11.27M |
| September 30, 2015 | 10.60M |
| June 30, 2015 | 9.774M |
| March 31, 2015 | 7.588M |
| December 31, 2014 | 4.274M |
| September 30, 2014 | 2.924M |
| June 30, 2014 | 2.596M |
| March 31, 2014 | 2.151M |
| December 31, 2013 | 2.630M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Decoy Therapeutics, Inc. | 1.304M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |